Posted by Michael Wonder on 26 Jul 2019
Innovative treatment for gynaecological cancers approved for Cancer Drugs Fund
26 July 2019 - Olaparib, a medicine that has previously been used at a later stage in the treatment of advanced ovarian cancer, has now been approved by NICE as a first-line maintenance treatment.
This positive recommendation affects adults with BRCA mutation-positive, advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to chemotherapy.
Currently around 700 women with advanced ovarian cancer are expected to benefit from this new treatment option.
